Tanabe Pharma Corporation

Diversified pharma (part of Mitsubishi Chemical Group)

Privately held: no public share price · Japan

Assets

(12 total)
12Total Assets
7Approved
4Phase 3 / Filed
1Phase 1–2 / Early
14Diseases
Quick filter:
Showing 12 of 12 assets
Target & Modality
Canagliflozin(Invokana)
Approved
SGLT2Small molecule
Type 2 DiabetesChronic Kidney Disease
Approved
Dopamine D3/D2 receptor (partial agonist)Small molecule
Major Depressive DisorderSchizophreniaBipolar DisorderBipolar Depression
Approved
Sphingosine 1-phosphate receptor (S1PR, specifically S1P1) · S1P receptor · Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)Small molecule
Multiple Sclerosis
Approved
CD19Monoclonal antibody
Systemic Lupus ErythematosusMyasthenia Gravis
Generalized Myasthenia Gravis
Approved
GLP-1/GIP receptor (dual)Peptide
Type 2 DiabetesAtherosclerotic Cardiovascular Disease
Vadadustat(Vafseo)
Approved
HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule
Chronic Kidney Disease
Valbenazine(Ingrezza)
Approved
vesicular monoamine transporter 2 (VMAT2)Small molecule
Tardive DyskinesiaHuntington's Disease
Huntington's Disease Chorea
AST-120(Kremezin)
Phase 3
Oral spherical carbon adsorbentSmall molecule
Chronic Kidney Disease
Phase 3
CETPSmall molecule
Type 2 DiabetesAtherosclerotic Cardiovascular DiseaseAlzheimer's Disease
Early Alzheimer's Disease
Sarpogrelate(Anplag)
Phase 3
Serotonin 5-HT2A receptor (antagonist / inverse agonist)Small molecule
Atherosclerotic Cardiovascular Disease
Teneligliptin(Tenelia)
Phase 3
DPP-4Small molecule
Type 2 Diabetes
Phase 2
S1P receptorSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis, Crohn's Disease

Upcoming events

(14 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
November 2026 (2)
ObicetrapibPhase 2Dyslipidemias
Est. primary completion 2026-11 · NCT06496243 · CT.gov ↗
What to watch
ObicetrapibPhase 3Atherosclerotic Cardiovascular Disease
Est. primary completion 2026-11 · NCT05202509 · CT.gov ↗
What to watch
December 2026 (1)
Cariprazine (Vraylar)Phase 3Schizophrenia
Est. primary completion 2026-12-15 · NCT03817502 · CT.gov ↗
What to watch
2027 (2)
March 2027 (1)
Cariprazine (Vraylar)Phase 3Depression, Bipolar I Disorder
Est. primary completion 2027-03 · NCT04777357 · CT.gov ↗
What to watch
April 2027 (1)
InebilizumabPhase 2Neuromyelitis Optica Spectrum Disorder
Est. primary completion 2027-04-13 · NCT05549258 · CT.gov ↗
What to watch
2028 (4)
March 2028 (1)
ObicetrapibPhase 3Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
Est. primary completion 2028-03 · NCT07219602 · CT.gov ↗
What to watch
April 2028 (1)
Valbenazine · IngrezzaPhase 3Chorea, Huntington
Est. primary completion 2028-04 · NCT06312189 · CT.gov ↗
What to watch
August 2028 (1)
InebilizumabPhase 2Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
Est. primary completion 2028-08-06 · NCT06570798 · CT.gov ↗
What to watch
September 2028 (1)
ObicetrapibPhase 2Preclinical Alzheimer's Disease
Est. primary completion 2028-09 · NCT07794670 · CT.gov ↗
What to watch
2030 (2)
March 2030 (1)
InebilizumabPhase 2Generalized Myasthenia Gravis
Est. primary completion 2030-03-13 · NCT06987539 · CT.gov ↗
What to watch
August 2030 (1)
Tirzepatide (Mounjaro)Phase 3Metabolic Dysfunction-Associated Steatotic Liver Disease
Est. primary completion 2030-08 · NCT07165028 · CT.gov ↗
What to watch
2031 (3)
June 2031 (1)
InebilizumabPhase 2Immunoglobulin G4-related Disease
Est. primary completion 2031-06-10 · NCT07222553 · CT.gov ↗
What to watch
July 2031 (1)
InebilizumabPhase 3Autoimmune Hepatitis, AIH
Est. primary completion 2031-07-30 · NCT07598825 · CT.gov ↗
What to watch
September 2031 (1)
InebilizumabPhase 3Glomerulonephritis, Membranous
Est. primary completion 2031-09-27 · NCT07851220 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(16)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

5 November 2026Topline resultVadadustatVOCAL meets its non-inferiority primary endpoint
Akebia Therapeutics · Source ↗
21 September 2026ApprovalObicetrapibEuropean Commission approves Ubeslo (obicetrapib)
EU, EC · NewAmsterdam Pharma and Menarini Group · Source ↗
28 August 2026ApprovaltirzepatideFDA approves Mounjaro to reduce cardiovascular risk in type 2 diabetes
US, FDA · Source ↗
27 August 2026ApprovalTirzepatide (Mounjaro)FDA Boxed Warning on Mounjaro (NDA215866)
US, FDA · FDA · Source ↗
June 2026Topline resultVadadustatVOICE interim analysis met the predefined stopping criteria (non-inferiority and superiority on the primary composite endpoint)
12 February 2026ApprovalInebilizumabEuropean Commission approves UPLIZNA for generalized myasthenia gravis
EU, EC · Source ↗
22 December 2025Topline resultValbenazine (Ingrezza)KINECT-DCP Phase 3 misses primary and key secondary endpoints
Neurocrine Biosciences · Source ↗
11 December 2025ApprovalInebilizumabFDA approves UPLIZNA for generalized myasthenia gravis
US, FDA · Amgen · Source ↗
December 2025Topline resultValbenazineKINECT-DCP Phase 3 (NCT05206513) did not meet its primary or key secondary endpoints
Neurocrine Biosciences · Source ↗
18 August 2025Filing acceptedObicetrapibEMA validates obicetrapib MAA
EU, EMA · Source ↗
3 April 2025ApprovalInebilizumabFDA approves UPLIZNA for IgG4-RD
US, FDA · Source ↗
27 February 2025Topline resultValbenazineKINECT-PRO Phase 4 top-line patient-reported outcome data

The 12 most recent of 16 past events are shown.

Financial reports

No financial reports recorded.